Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genesco (GCO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Genesco (GCO) over the last 16 years, with Q4 2025 value amounting to -$2.9 million.

  • Genesco's Change in Accured Expenses rose 181.15% to -$2.9 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$2.4 million, marking a year-over-year decrease of 13166.53%. This contributed to the annual value of $12.1 million for FY2025, which is 70000.0% up from last year.
  • According to the latest figures from Q4 2025, Genesco's Change in Accured Expenses is -$2.9 million, which was up 181.15% from $9.7 million recorded in Q3 2025.
  • Genesco's 5-year Change in Accured Expenses high stood at $33.8 million for Q2 2021, and its period low was -$44.2 million during Q2 2022.
  • In the last 5 years, Genesco's Change in Accured Expenses had a median value of -$2.4 million in 2022 and averaged -$251350.0.
  • Over the last 5 years, Genesco's Change in Accured Expenses had its largest YoY gain of 31683.99% in 2025, and its largest YoY loss of 60370.71% in 2025.
  • Over the past 5 years, Genesco's Change in Accured Expenses (Quarter) stood at -$3.5 million in 2021, then soared by 141.33% to $1.4 million in 2022, then crashed by 264.68% to -$2.4 million in 2023, then dropped by 25.36% to -$3.0 million in 2024, then grew by 1.81% to -$2.9 million in 2025.
  • Its Change in Accured Expenses stands at -$2.9 million for Q4 2025, versus $9.7 million for Q3 2025 and -$15.2 million for Q2 2025.